Business
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10.
About this update from Eisai Co., Ltd.
[{"type":"text","content":"E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1","length":85,"tagName":"p","attribs":{}},{"type":"text","content":"TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10.","length":359,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/430b67e6c0e0ec77425af976ce7841b3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2e0GLvH6YUtAIoW563sHAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/430b67e6c0e0ec77425af976ce7841b3","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2766684/MWT_LSM_Sleep_Latency.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"These data demonstrate that once-daily dosing of E2086 has the potential to improve daytime wakefulness in individuals with narcolepsy type 1 (NT1).","length":148,"tagName":"p"},{"type":"text","content":"Clinical Trial DesignThis randomized, double-blind, single-dose, multiple crossover, Phase Ib clinical trial was conducted in the United States and Canada to evaluate the efficacy, safety, and tolerability of E2086 in people meeting criteria for NT1, compared with placebo and an existing treatment (modafinil). There were a total of 21 patients in the clinical trial (21 patients received the study medication, 19 patients completed the trial). Participants received a single dose of one of five treatments (E2086 5 mg, 10 mg, 25 mg, placebo, or modafinil) shortly after waking, efficacy assessments were conducted for each treatment.","length":641,"tagName":"p"},{"type":"text","content":"Efficacy was assessed using the objective Maintenance of Wakefulness Test (MWT)*1 to evaluate excessive daytime sleepiness (EDS), and subjective sleepiness was measured using the Karolinska Sleepiness Scale (KSS)*2 at the end of each MWT session.","length":246,"tagName":"p"},{"type":"text","content":"Clinical Tria...